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1076Prognostic Impact of Serum Immunoglobulin
Heavy/Light Chain Ratio in Patients with Multiple
Myeloma in Complete Remission after Autologous
Stem Cell Transplantation
Natalia Tovar,1 Carlos Fernandez de Larrea,1 Montserrat Elena,2 M. Teresa Cibeira,1
Juan I. Arostegui,3 Laura Rosi~nol,1 Xavier Filella,2 Jordi Yag€ue,3 Joan Blade1Immunoglobulin heavy/light chain (HLC) ratios were studied in 37 patients with multiple myeloma in
complete remission after autologous hematopoietic stem cell transplantation. Increased IgAk/IgAl and
IgMk/IgMl ratios were associated with longer progression-free survival (P 5 .006 and .01, respectively).
A statistical trend toward a longer overall survival was also observed for the IgAk/IgAl ratio (P 5 .068).
Considering the original immunoglobulin isotype, our results indicate that an increased k/l ratio of the
uninvolved isotype is associated with longer progression-free survival and overall survival. This is the first
report demonstrating the association between the HLC ratio and sustained complete remission in patients
with multiple myeloma. Our results suggest that the HLC ratio is a surrogate marker of immune recovery
after myeloablative transplantation, rather than as a marker of minimal residual disease.
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Complete remission (CR) in multiple myeloma
(MM) is defined by the absence of the original mono-
clonal protein in serum and urine immunofixations
(IFE) [1]. The International Myeloma Working
Group proposed the additional category of stringent
CR [2], which also requires a normal light chain k/l
ratio. However, the prognostic significance of this
novel category remains under investigation [3,4].
Furthermore, the presence of oligoclonal bands
unrelated to the original monoclonal component,
which is a frequent event after hematopoietic stem
cell transplantation (HSCT) or induction treatments
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outcome through a robust immune response [5,6].
Automatic assays for the measurement of serum
free immunoglobulin chains have been available for
a number of years and have proven useful in the screen-
ing, diagnosis, prognosis, and follow-up of monoclo-
nal gammopathies [7]. The recent development of
antibodies against conjunction epitopes between the
light and heavy chains enables the quantitation of spe-
cific pairs of heavy/light chains (HLCs: IgGk/IgGl,
IgAk/IgAl, and IgMk/IgMl) in serum, which allows
the determination of the quantity of tumoral immuno-
globulin [8]. The aim of the present study was to estab-
lish the possible value of the serum HLC ratios in
patients with MM in CR after HSCT.METHODS
A total of 193 patients with MM underwent
autologous HSCT (auto-HSCT) in our institution be-
tween March 31, 1994, and December 31, 2010. Of
these, 73 achieved CR according to European Blood
and Marrow Transplantation (EBMT) criteria. Our
analysis included 37 patients (17 males and 20 females;
median age, 57 years) who had serum samples available
at the time of CR confirmation. All of the patients had
achieved CR after melphalan-based auto-HSCT, and
Table 1. Patient Characteristics
Characteristic Value
Age, years, median (range) 57 (38-67)
Males/females, n 17/20
Heavy chain type, %
IgG 51.4
IgA 24.3
Light chains only 13.5
IgD 8.1
IgM 2.7
Light chain type, %
k 64.9
l 35.1
Durie-Salmon stage, %
I 10.8
II 56.8
III 32.4
International Staging System, %
1 56.8
2 27
3 16.2
b2-microglobulin >3.5 mg/dL, % 40.5
Albumin <35 g/L, % 16.2
Lytic bone lesions, % 86.1
Figure 2. Overall survival in the series according to the IgAk/IgAl ratio.
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monoclonal protein and \5% bone marrow plasma
cells [9]. The median duration of follow-up in CR
was 4 years (range, 1-17 years), and no patients were
lost during follow-up. Relapse and progression were
assessed based on EBMT criteria [1]. According to
the EBMT criteria, relapse from CR was defined by
the confirmed reappearance of the monoclonal band
in serum or urine, a .5% increase in plasma cells in
a bone marrow aspirate, or the development of hyper-
calcemia, increased size and/or number of lytic bone le-
sions, or extramedullary plasmacytomas. Patient
characteristics are detailed in Table 1. The main clini-
cal and laboratory characteristics were similar in this
group of patients and the remaining patients who
achieved CR but who were not analyzed due to lackFigure 1. Progression-free survival in the series according to the IgAk/
IgAl ratio.of sample availability. The study was approved by the
Ethics Committee of the Hospital Clınic of Barcelona.
An oligoclonal band was defined as the presence of
a heavy and/or light monoclonal immunoglobulin by
IFE in serum and/or urine different from the original
monoclonal protein [7]. Serum HLC was assayed by
immunonephelometry (Hevylite Assay; Binding Site,
Birmingham, U.K.), and ratios were determined for
each isotype (IgG, IgA, and IgM). Statistical analysis
was performed with PASW 18.0 for Windows
(IBM, New York, NY). Categorical variables were
compared using the c2 test or the Fisher exact test,
and median differences were compared using analysis
of variance or the Student t test. Probabilities of overall
survival (OS) and progression-free survival (PFS) were
estimated with the Kaplan-Maier method and com-
pared using the log-rank test.RESULTS AND DISCUSSION
Thirty-three of the 37 patients (89.2%) were alive
at the time of this analysis; however, 11 (29.7%) had al-
ready relapsed from CR. The median PFS and OS
from CR were not reached. Induction treatment con-
sisted of bortezomib-based regimens in 15 patients,
polychemotherapy in 12 patients, and thalidomide/
dexamethasone in 9 patients.
The median values obtained in our patients were
not significantly different from the data reported previ-
ously in a normal population [8]. Subsequently, we di-
chotomized our group of patients according to the
median value for eachpair ofHLCisotypes. Inour anal-
ysis, the IgGk/IgGl ratiowasnot associatedwith signif-
icant differences in PFSorOS. An increased IgAk/IgAl
ratio was associated with a longer PFS (P 5 .006) and
with a statistical trend toward a longer OS (P 5 .068)
(Figures 1 and 2). Similarly, an increased IgMk/IgMl
ratio correlated with a longer PFS (P 5 .01) and with
1078 Biol Blood Marrow Transplant 18:1076-1079, 2012N. Tovar et al.a trend toward a longer OS (P 5 .159). Regarding the
original isotype, neitherPFSnorOSwasmodified in re-
lation to the IgGk/IgGl ratio in those patients with an
original monoclonal IgG isotype; however, low IgAk/
IgAl and IgMk/IgMl ratios were associated with
a shorter PFS (P 5 .038 and .006, respectively). In the
patients with an original monoclonal IgA isotype,
a lower IgGk/IgGl ratio was also associated with
shorter PFS (P 5 .036), but no association with the
IgA or IgM ratio was observed.
The achievement of CR, with negative serum and
urine IFEs, is the most significant prognostic factor
in MM [10,11]. Different CR categories are
associated with different prognostic impacts. Thus,
patients in CR (negative IFEs) without minimal
residual disease (MRD) by flow cytometry have
a significantly longer PFS and OS compared with
those in CR with MRD [12]. In this context, the
opportunity to measure HLC ratios provides a new
tool for assessing the response to treatment in MM;
however, its prognostic utility has not yet been deter-
mined.
Our results indicate that increased IgAk/IgAl and
IgMk/IgMl ratios of the uninvolved isotype in pa-
tients in CR is associated with longer PFS and OS.
Thus, in those patients with MM with an original
monoclonal IgG protein who achieved CR, PFS was
significantly longer when IgA k/l or IgM k/l ratios
were increased. In this sense, the HLC ratio seems to
be a marker of immune reconstitution rather than an
indicator of MRD, even though the median values
were very close to those reported in the normal popu-
lation. We found no differences in OS or PFS related
to an increased serum immunoglobulin level over the
median value for IgA, IgG, or IgM. In fact, we found
no correlation between a relatively higher HLC ratio
and the corresponding isotype in total immunoglobu-
lins. This represents an additional benefit of measuring
HLC ratios over total immunoglobulin levels. Sup-
porting this, the FrenchMyeloma Intergroup reported
that theHLC ratio can provide ameasure of tumor im-
munoglobulin production and immunoparesis, and
thus would be a useful prognostic factor to add to
the current International Staging System [13]. These
authors also reported that an abnormal HLC ratio
was associated with a shorter PFS independent of
b2-microglobulin and albumin [13]. The Mayo group
is also currently investigating the possible value of
isotype-specific HLC suppression of uninvolved im-
munoglobulins as a predictor of progression in mono-
clonal gammopathy of undetermined significance
(MGUS). They reported a series of 30 patients with
MGUS who progressed to MM versus 36 patients
who did not progress over a similar period of time.
Those with MGUS progression had a significantly
higher rate of isotype-specific HLC pair suppression
than those with stable MGUS [14].Oligoclonal bands were detected in 64.9% of pa-
tients in our series. Of these, 91.7% demonstrated an
IgG isotype. No light chain predominance was noted.
A second oligoclonal band was found in 29.7% of the
cases. In the overall series, no significant relationship
between oligoclonal bands and the IgG, IgA, or IgM
ratio was detected. Associated with the progressive im-
provement in CR rates with auto-HSCT, some studies
have related the presence of oligoclonal bands (a hu-
moral response unrelated to the baseline M-protein)
to better outcome [15]. In a previous study, we
reported that 40% of the patients in CR after auto-
HSCT presented oligoclonal bands resulting in an
elevation in the free light chain (FLC) k/l ratio [6].
Increased oligoclonal bands are also seen in patients
in CR after immunomodulatory drug therapy [5,16].
In contrast with previous studies that reported
modification of the FLC ratio by the presence of
oligoclonal bands, there is no evidence that a heavy
isotype pair also could be altered by this immune
phenomenon. Based on the different nature of the
immunoglobulin studied, the meaning of FLC and
HLC ratios at diagnosis, prognosis, and follow-up
appears to be different. Unlike the FLC ratio, the
HLC ratio does not seem to be affected by renal func-
tion, given the different excretion pathway of FLCs
and HLCs, although there are no specific published
data on this. No studies regarding the potential role
of active infections or drugs in HLC ratio determina-
tion have been reported to date. Similarly, immuno-
globulin infusions could potentially modify this
value, but this is not the case in the present study, given
that none of our patients had immunoglobulin reposi-
tioning after transplantation.
In conclusion, our data indicate that a relatively
higher HLC ratio of the uninvolved immunoglobulin
is predictor for a significantly longer PFS and even
OS in patients with MM in CR. Because HLC ratios
provide a measure of tumor immunoglobulin produc-
tion plus immunoparesis rather than a marker of
MRD, this parameter is more likely a surrogate marker
of robust immune recovery. Further studies investigat-
ing potential roles of HLC measurement in MM are
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